While we have focused here on DDR1 and DDR2 in breast and ovarian cancer, they are increasingly important and relevant anti-cancer targets for multiple tumor types (Lafitte et al., 2020; Bhanumathy et al., 2021; Gao et al., 2021). Here, DDR2 is linked to ovarian cancer.